Metabolic topology of neurodegenerative disorders: Influence of cognitive and motor deficits

Journal of Nuclear Medicine

Volumn 56, Issue 12, 2015, Pages 1916-1921

  Granert, Oliver ^a   Drzezga, Alexander E ^b   Boecker, Henning ^c   Perneczky, Robert ^d,e,f   Kurz, Alexander ^f   Gotz, Julia ^a   Van Eimeren, Thilo ^a   Haussermann, Peter ^a,b  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e WEST LONDON MENTAL HEALTH NHS TRUST   (United Kingdom)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Alzheimer; Dementia; FDG PET; Motor deficits; Parkinson

Indexed keywords

GLUCOSE; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

AGED; AMNESIA; ARTICLE; BRAIN MAPPING; BRAIN METABOLISM; CLINICAL FEATURE; COGNITIVE DEFECT; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL; ALZHEIMER DISEASE; COGNITION; DEGENERATIVE DISEASE; IMAGE PROCESSING; METABOLISM; PSYCHOLOGY; SCINTISCANNING;

AGED; ALZHEIMER DISEASE; BRAIN MAPPING; COGNITION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LEWY BODY DISEASE; MALE; MILD COGNITIVE IMPAIRMENT; MOVEMENT DISORDERS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; PARKINSON DISEASE, POSTENCEPHALITIC; RADIOPHARMACEUTICALS;

EID: 84958241018     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.156067     Document Type: Article

References (36)

1. Ballard C, Ziabreva I, Perry R, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology. 2006;67:1931-1934.
2. Ince PG, Perry EK, Morris CM. Dementia with Lewy bodies: a distinct non-Alzheimer dementia syndrome? Brain Pathol. 1998;8:299-324.
3. Perl DP, Olanow CW, Calne D. Alzheimer's disease and Parkinson's disease: distinct entities or extremes of a spectrum of neurodegeneration? Ann Neurol. 1998;44:S19-S31.
4. Galpern WR, Lang AE. Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol. 2006;59:449-458.
5. Perry EK, Irving D, Kerwin JM, et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord. 1993;7:69-79.
6. Moussaud S, Jones DR, Moussaud-Lamodière EL, Delenclos M, Ross OA, McLean PJ. Alpha-synuclein and tau: teammates in neurodegeneration? Mol Neurodegener. 2014;9:43.
7. Irwin DJ, Lee VM-Y, Trojanowski JQ. Parkinson's disease dementia: convergence of a-synuclein, tau and amyloid-b pathologies. Nat Rev Neurosci. 2013;14: 626-636.
8. Bertens D, Knol DL, Scheltens P, Visser PJ. Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease. Alzheimers Dement. 2015;11:511-522.
9. Lundström SL, Yang H, Lyutvinskiy Y, et al. Blood plasma IgG Fc glycans are significantly altered in Alzheimer's disease and progressive mild cognitive impairment. J Alzheimers Dis. 2014;38:567-579.
10. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007;22:1689-1707.
11. Herholz K. FDG PET and differential diagnosis of dementia. Alzheimer Dis Assoc Disord. 1995;9:6-16.
12. Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic topography of parkin-sonism. J Cereb Blood Flow Metab. 1994;14:783-801.
13. Ma Y, Tang C, Spetsieris PG, Dhawan V, Eidelberg D. Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. J Cereb Blood Flow Metab. 2007;27:597-605.
14. Teune LK, Bartels AL, de Jong BM, et al. Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord. 2010;25:2395-2404.
15. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
16. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neu-rol Neurosurg Psychiatry. 1992;55:181-184.
17. Fahn S. Assessment of the primary dystonias. In: Munsat T, ed. The Quantification of Neurologic Deficit. Oxford, U.K.: Butterworths; 1989:241-270.
18. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis. 2006;9:417-423.
19. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment: beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256:240-246.
20. Berres M, Monsch AU, Bernasconi F, Thalmann B, Stähelin HB. Normal ranges of neuropsychological tests for the diagnosis of Alzheimer's disease. Stud Health Technol Inform. 2000;77:195-199.
21. Soriano-Mas C, Pujol J, Alonso P, et al. Identifying patients with obsessive-compulsive disorder using whole-brain anatomy. Neuroimage. 2007;35:1028-1037.
22. Worsley KJ, Poline JB, Vandal AC, Friston KJ. Tests for distributed, nonfocal brain activations. Neuroimage. 1995;2:183-194.
23. 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med. 1997;24:320-325.
24. Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuro-image. 2002;17:302-316.
25. Meltzer CC, Zubieta JK, Brandt J, Tune LE, Mayberg HS, Frost JJ. Regional hypometabolism in Alzheimer's disease as measured by positron emission tomography after correction for effects of partial volume averaging. Neurology. 1996;47:454-461.
26. Tam CWC, Burton EJ, McKeith IG, Burn DJ, O'Brien JT. Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies. Neurology. 2005;64:861-865.
27. 18F]FDG-PET. Mov Disord. 2001;16:1014-1022.
28. Antonini A, Vontobel P, Psylla M, et al. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch Neurol. 1995;52:1183-1190.
29. Antonini A, De Notaris R, Benti R, De Gaspari D, Pezzoli G. Perfusion ECD/SPECT in the characterization of cognitive deficits in Parkinson's disease. Neu-rol Sci. 2001;22:45-46.
30. Firbank MJ, Colloby SJ, Burn DJ, McKeith IG, O'Brien JT. Regional cerebral blood flow in Parkinson's disease with and without dementia. Neuroimage. 2003;20:1309-1319.
31. Kuhl DE, Metter EJ, Riege WH, Markham CH. Patterns of cerebral glucose utilization in Parkinson's disease and Huntington's disease. Ann Neurol. 1984; 15(suppl):S119-S125.
32. Piert M, Koeppe RA, Giordani B, Minoshima S, Kuhl DE. Determination of regional rate constants from dynamic FDG-PET studies in Parkinson's disease. J Nucl Med. 1996;37:1115-1122.
33. Garibotto V, Montandon ML, Viaud CT, et al. Regions of interest-based discriminant analysis of DaTSCAN SPECT and FDG-PET for the classification of dementia. Clin Nucl Med. 2013;38:e112-e117.
34. Vander Borght T, Minoshima S, Giordani B, et al. Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. J Nucl Med. 1997;38:797-802.
35. Weintraub D, Dietz N, Duda JE, et al. Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. Brain. 2012;135: 170-180.
36. Peng S, Eidelberg D, Ma Y. Brain network markers of abnormal cerebral glucose metabolism and blood flow in Parkinson's disease. Neurosci Bull. 2014;30:823-837.